Development of new therapeutics for multiple myeloma that uses myeloma cell targeting sgRNA and microenvirament targeting sgRNA
| Project/Area Number |
15H04313
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
青木 定夫 新潟薬科大学, 薬学部, 教授 (40242408)
高橋 益廣 新潟大学, 医歯学系, 教授 (90179531)
|
|---|
| Research Collaborator |
HAINO Arisa
ISHIKAWA Tatsuya
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Keywords | 核酸医薬 / 多発性骨髄腫 / sgRNA / TRUE gene silencing / マクロファージ / 腫瘍微小環境 / 核酸治療 / がん / RNA治療 / 血液がん / がん微小環境 / gene silencing |
|---|
| Outline of Final Research Achievements |
Multiple myeloma is the second most common refractory hematological malignancy. Although mean survival is extended by development of new molecular target drugs made of small molecules or antibodies, drug-resistant myeloma cells emerge in most of the patients and result in subsequent relapse of cancer.
We have developed TRUE gene silencing as a gene expression suppression technology using sgRNA, and our final goal is to discover therapeutic sgRNAs to cure multiple myeloma. In this study, we found a candidate sgRNA drug that can change macrophages that support myeloma growth to those that attack myeloma cells, and demonstrated that this sgRNA drug can suppress tumor growth in a mouse model experiment.
|
Report
(4 results)
Research Products
(6 results)
